MAP Pharmaceuticals Inc. said that its potential treatment for asthma in children did not improve symptoms any better than placebo in a Phase III study of unit dose budesonide (UDB), leaving the program in limbo for now and causing its shares to fall more than 75 percent. (BioWorld Today) Read More
No Abstract BioWorld Today CorrespondentDUBLIN, Ireland - Opsona Therapeutics Ltd. raised €18 million (US$23 million) in a Series B round and unveiled a research and collaboration agreement with CSL Ltd., based on the identification of novel vaccine adjuvant formulations using its proprietary OpsoVac immunotherapy platform. Read More
